DelSiTech is an innovative drug delivery and development company that works with its partners to turn their active agents into novel, viable therapeutics.
Today Visus announced worldwide exclusive agreements with Cella Therapeutics and @DelSiTech to expand our #ophthalmic drug portfolio with investigational therapies for #glaucoma and age-related macular degeneration.
Read the full release➡️ bwnews.pr/2UyYGuo#opthotwitter
“In low- and middle-income countries, there are still tens of millions of #women who need support for family planning, and individuals at risk of #HIV infection in need of better #prevention measures,” @DelSiTech. 🙎🏽♀️#LMIC#biotechbit.ly/2KYkI2z
#RAReports
Technologies designed to deliver more than one type of biologic product are 3DNA (@Genisphere ), DelSiTechTMSilica Matrix (@DelSiTech ), HEPtunetechnology (Caisson Biotech), PLEX Texhnology (PolyPid), V-Smart Platform (@LaurenSciencesbit.ly/2GmIEdw
#RAReports#Novel#technologies for Delivery of Proteins, Antibodies & Nucleic Acids
Market landscape of companies offering technologies for delivery of biotherapeutics, types of biologics delivered, routes of administration & impact on patient compliance
bit.ly/2GmIEdw